Bisphosphonate treatment in osteogenesis imperfecta: Which drug, for whom, for how long?

References

• Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377–85.
   PubMed Web of Science ®Google Scholar
• Shapiro JR, Stover ML, Burn VE, McKinstry MB, Burshell AL, Chipman SD, et al. An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen. J Clin Invest. 1992;89:567–73.
   PubMedGoogle Scholar
• Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.
   Google Scholar
• Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17:30–8.
   PubMed Web of Science ®Google Scholar
• Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000;15: 1650–8.
   PubMed Web of Science ®Google Scholar
• Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an auto-somal recessive form of brittle bone disease. Bone. 2002;31: 12–8.
   PubMed Web of Science ®Google Scholar
• Engelbert RH, Pruijs HE, Beemer FA, Helders PJ. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil. 1998;79:1590–4.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003;12:77–87.
   PubMed Web of Science ®Google Scholar
• Engelbert RH, Beemer FA, van der Graaf Y, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability-a follow-up study. Arch Phys Med Rehabil. 1999;80:896–903.
   PubMed Web of Science ®Google Scholar
• Gerber LH, Binder H, Berry R, Siegel KL,, Kim H, Weintrob J, et al. Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Arch Phys Med Rehabil. 1998;79:46–51.
   PubMed Web of Science ®Google Scholar
• Wilkinson JM, Scott BW, Clarke AM, Bell MJ. Surgical stabilisation of the lower limb in osteogenesis imperfecta using the Sheffield Telescopic Intramedullary Rod System. J Bone Joint Surg Br. 1998;80:999–1004.
   PubMedGoogle Scholar
• Karbowski A, Schwitalle M, Brenner R, Lehmann H, Pontz B, Worsdorfer 0. Experience with Bailey-Dubow rodding in children with osteogenesis imperfecta. Eur J Pediatr Surg. 2000;10:119–24.
   Google Scholar
• Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29:553–9.
   Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100.
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphospho-nate treatment with APD in a child suffering from osteogen-esis imperfecta. Skeletal Radiol. 1987;16:360–3.
   Google Scholar
• Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339:947–52.
   PubMed Web of Science ®Google Scholar
• Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imper-fecta. Arch Dis Child. 2002;86:356–64.
   PubMed Web of Science ®Google Scholar
• Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogen-esis imperfecta in children under 3 years of age. J Chin Endocrinol Metab. 2000;85: 1846–50.
   Google Scholar
• Zacharin M, Bateman J. Pamidronate treatment of osteogen-esis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002;15: 163–74.
   PubMedGoogle Scholar
• Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18:610–4.
   PubMedGoogle Scholar
• Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moder-ate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004;34: 539–46.
   PubMedGoogle Scholar
• Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res. 2004;61: 137–42.
   Google Scholar
• Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110:1293–9.
   PubMed Web of Science ®Google Scholar
• Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone. 2003;32:268–74.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics. 2003;111:1030–6.
   PubMed Web of Science ®Google Scholar
• Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18:126–30.
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmeno-pausal women with low bone mineral density. N Engl J Med. 2002;346:653–61.
   PubMed Web of Science ®Google Scholar
• Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr. 2003;92:452–5.
   Google Scholar
• Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363: 1427–31.
   Google Scholar
• Grissom LE, Harcke HT. Radiographic features of bispho-sphonate therapy in pediatric patients. Pediatr Radiol. 2003;33:226–9.
   PubMedGoogle Scholar
• Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19: 1191–3.
   PubMedGoogle Scholar
• Leonard MB. Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques. Med Pediatr Oncol. 2003;41:198–207.
   PubMedGoogle Scholar
• Fewtrell MS. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003;88:795–8.
   PubMed Web of Science ®Google Scholar
• Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorpho-metry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003:103–12.
   PubMedGoogle Scholar
• Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 1996;11:150–9.
   Google Scholar
• Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Chin Endocrinol Metab. 2003;88:986–92.
   Google Scholar
• Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349:457–63.
   PubMed Web of Science ®Google Scholar
• Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res. 1994;9:1777–87.
   PubMedGoogle Scholar
• Roschger P, Grabner BM, Rinnerthaler S, Tesch W, Kneissel M, Berzlanovich A, et al. Structural development of the mineralized tissue in the human L4 vertebral body. J Struct Biol. 2001;136:126–36.
   PubMedGoogle Scholar
• Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779–86.
   Google Scholar
• Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700–7.
   PubMed Web of Science ®Google Scholar
• Munns CF, Rauch F, Ward L, Glorieux FH. Effect of prenatal pamidronate therapy on maternal and fetal outcome: A report of two cases. J Bone Miner Res. 2004;19:1742–5.
   PubMed Web of Science ®Google Scholar
• Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001;160:641–4.
   PubMedGoogle Scholar
• Banerjee I, Shortland GJ, Evans WD, Gregory JW. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child. 2002;87:562–3.
   PubMedGoogle Scholar
• Giraud F, Meunier PJ. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imper-fecta. Open-label study in seven patients. Joint Bone Spine. 2002;69:486–90.
   PubMedGoogle Scholar
• Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003;111: 573–8.
   PubMed Web of Science ®Google Scholar